News | April 11, 2024
Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
A game changing solution for the pharmaceutical industry
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Subscribe To Our Newsletter & Stay Updated
